ENTRADA THERAPEUTICS INC (TRDA) — insider trading
Health Care · NASDAQ
ENTRADA THERAPEUTICS INC (TRDA) has 53 reported SEC Form 4 insider transactions in our data, including 1 open-market purchase and 40 open-market sales among the most recent 53 (latest 2026-09-09).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-09 | MPM BIOVENTURES 2018, L.P.; MPM BioVentures 2018 LLC; MPM BioVentures 2018 GP LLC | 10% owner | Open-market sale | 28,837 | $7.13 | $205.6K | Form 4 |
| 2026-09-09 | MPM BioVentures 2014, L.P.; EVNIN LUKE; GADICKE ANSBERT; Foley Todd; MPM BioVentures 2014 (B), L.P.; MPM Asset Management Investors BV2014 LLC; MPM BioVentures 2014 LLC; MPM BioVentures 2014 GP LLC; MPM BIOVENTURES 2018 (B), L.P.; MPM ASSET MANAGEMENT INVESTORS BV2018 LLC | 10% owner | Open-market sale | 28,837 | $7.13 | $205.6K | Form 4 |
| 2026-09-08 | MPM BIOVENTURES 2018, L.P.; MPM BioVentures 2018 LLC; MPM BioVentures 2018 GP LLC | 10% owner | Open-market sale | 192,500 | $7.41 | $1.43M | Form 4 |
| 2026-09-08 | MPM BioVentures 2014, L.P.; EVNIN LUKE; GADICKE ANSBERT; Foley Todd; MPM BioVentures 2014 (B), L.P.; MPM Asset Management Investors BV2014 LLC; MPM BioVentures 2014 LLC; MPM BioVentures 2014 GP LLC; MPM BIOVENTURES 2018 (B), L.P.; MPM ASSET MANAGEMENT INVESTORS BV2018 LLC | 10% owner | Open-market sale | 192,500 | $7.41 | $1.43M | Form 4 |
| 2026-09-04 | MPM BIOVENTURES 2018, L.P.; MPM BioVentures 2018 LLC; MPM BioVentures 2018 GP LLC | 10% owner | Open-market sale | 38,500 | $7.11 | $273.7K | Form 4 |
| 2026-09-04 | MPM BioVentures 2014, L.P.; EVNIN LUKE; GADICKE ANSBERT; Foley Todd; MPM BioVentures 2014 (B), L.P.; MPM Asset Management Investors BV2014 LLC; MPM BioVentures 2014 LLC; MPM BioVentures 2014 GP LLC; MPM BIOVENTURES 2018 (B), L.P.; MPM ASSET MANAGEMENT INVESTORS BV2018 LLC | 10% owner | Open-market sale | 38,500 | $7.11 | $273.7K | Form 4 |
| 2026-09-03 | MPM BIOVENTURES 2018, L.P.; MPM BioVentures 2018 LLC; MPM BioVentures 2018 GP LLC | 10% owner | Open-market sale | 32,263 | $7.17 | $231.3K | Form 4 |
| 2026-09-03 | MPM BioVentures 2014, L.P.; EVNIN LUKE; GADICKE ANSBERT; Foley Todd; MPM BioVentures 2014 (B), L.P.; MPM Asset Management Investors BV2014 LLC; MPM BioVentures 2014 LLC; MPM BioVentures 2014 GP LLC; MPM BIOVENTURES 2018 (B), L.P.; MPM ASSET MANAGEMENT INVESTORS BV2018 LLC | 10% owner | Open-market sale | 32,263 | $7.17 | $231.3K | Form 4 |
| 2026-09-02 | Sethuraman Natarajan | Officer (President, Research & Develop.) | Shares withheld for taxes / exercise cost | 2,079 | $7.14 | $14.9K | Form 4 |
| 2026-09-02 | WENTWORTH KORY JAMES | Officer (Chief Financial Officer) | Shares withheld for taxes / exercise cost | 1,733 | $7.14 | $12.4K | Form 4 |
| 2026-09-02 | MPM BIOVENTURES 2018, L.P.; MPM BioVentures 2018 LLC; MPM BioVentures 2018 GP LLC | 10% owner | Open-market sale | 25,131 | $7.19 | $180.7K | Form 4 |
| 2026-09-02 | MPM BioVentures 2014, L.P.; EVNIN LUKE; GADICKE ANSBERT; Foley Todd; MPM BioVentures 2014 (B), L.P.; MPM Asset Management Investors BV2014 LLC; MPM BioVentures 2014 LLC; MPM BioVentures 2014 GP LLC; MPM BIOVENTURES 2018 (B), L.P.; MPM ASSET MANAGEMENT INVESTORS BV2018 LLC | 10% owner | Open-market sale | 25,131 | $7.19 | $180.7K | Form 4 |
| 2026-09-02 | Dowden Nathan J | Officer (President & COO) | Shares withheld for taxes / exercise cost | 2,528 | $7.14 | $18.1K | Form 4 |
| 2026-09-02 | Doshi Dipal | Director, Officer (CEO) | Shares withheld for taxes / exercise cost | 8,724 | $7.14 | $62.3K | Form 4 |
| 2026-09-01 | MPM BIOVENTURES 2018, L.P.; MPM BioVentures 2018 LLC; MPM BioVentures 2018 GP LLC | 10% owner | Open-market sale | 29,088 | $7.06 | $205.4K | Form 4 |
| 2026-09-01 | MPM BioVentures 2014, L.P.; EVNIN LUKE; GADICKE ANSBERT; Foley Todd; MPM BioVentures 2014 (B), L.P.; MPM Asset Management Investors BV2014 LLC; MPM BioVentures 2014 LLC; MPM BioVentures 2014 GP LLC; MPM BIOVENTURES 2018 (B), L.P.; MPM ASSET MANAGEMENT INVESTORS BV2018 LLC | 10% owner | Open-market sale | 29,088 | $7.06 | $205.4K | Form 4 |
| 2026-08-31 | MPM BIOVENTURES 2018, L.P.; MPM BioVentures 2018 LLC; MPM BioVentures 2018 GP LLC | 10% owner | Open-market sale | 44,259 | $6.99 | $309.4K | Form 4 |
| 2026-08-31 | MPM BioVentures 2014, L.P.; EVNIN LUKE; GADICKE ANSBERT; Foley Todd; MPM BioVentures 2014 (B), L.P.; MPM Asset Management Investors BV2014 LLC; MPM BioVentures 2014 LLC; MPM BioVentures 2014 GP LLC; MPM BIOVENTURES 2018 (B), L.P.; MPM ASSET MANAGEMENT INVESTORS BV2018 LLC | 10% owner | Open-market sale | 44,259 | $6.99 | $309.4K | Form 4 |
| 2026-08-28 | MPM BIOVENTURES 2018, L.P.; MPM BioVentures 2018 LLC; MPM BioVentures 2018 GP LLC | 10% owner | Open-market sale | 3,733 | $7.01 | $26.2K | Form 4 |
| 2026-08-28 | MPM BioVentures 2014, L.P.; EVNIN LUKE; GADICKE ANSBERT; Foley Todd; MPM BioVentures 2014 (B), L.P.; MPM Asset Management Investors BV2014 LLC; MPM BioVentures 2014 LLC; MPM BioVentures 2014 GP LLC; MPM BIOVENTURES 2018 (B), L.P.; MPM ASSET MANAGEMENT INVESTORS BV2018 LLC | 10% owner | Open-market sale | 3,733 | $7.01 | $26.2K | Form 4 |
| 2026-08-27 | MPM BIOVENTURES 2018, L.P.; MPM BioVentures 2018 LLC; MPM BioVentures 2018 GP LLC | 10% owner | Open-market sale | 38,922 | $7.20 | $280.2K | Form 4 |
| 2026-08-27 | MPM BioVentures 2014, L.P.; EVNIN LUKE; GADICKE ANSBERT; Foley Todd; MPM BioVentures 2014 (B), L.P.; MPM Asset Management Investors BV2014 LLC; MPM BioVentures 2014 LLC; MPM BioVentures 2014 GP LLC; MPM BIOVENTURES 2018 (B), L.P.; MPM ASSET MANAGEMENT INVESTORS BV2018 LLC | 10% owner | Open-market sale | 38,922 | $7.20 | $280.2K | Form 4 |
| 2026-08-26 | MPM BIOVENTURES 2018, L.P.; MPM BioVentures 2018 LLC; MPM BioVentures 2018 GP LLC | 10% owner | Open-market sale | 14,569 | $7.06 | $102.9K | Form 4 |
| 2026-08-26 | MPM BioVentures 2014, L.P.; EVNIN LUKE; GADICKE ANSBERT; Foley Todd; MPM BioVentures 2014 (B), L.P.; MPM Asset Management Investors BV2014 LLC; MPM BioVentures 2014 LLC; MPM BioVentures 2014 GP LLC; MPM BIOVENTURES 2018 (B), L.P.; MPM ASSET MANAGEMENT INVESTORS BV2018 LLC | 10% owner | Open-market sale | 14,569 | $7.06 | $102.9K | Form 4 |
| 2026-08-25 | MPM BIOVENTURES 2018, L.P.; MPM BioVentures 2018 LLC; MPM BioVentures 2018 GP LLC | 10% owner | Open-market sale | 26,522 | $7.54 | $200.0K | Form 4 |
| 2026-08-25 | MPM BioVentures 2014, L.P.; EVNIN LUKE; GADICKE ANSBERT; Foley Todd; MPM BioVentures 2014 (B), L.P.; MPM Asset Management Investors BV2014 LLC; MPM BioVentures 2014 LLC; MPM BioVentures 2014 GP LLC; MPM BIOVENTURES 2018 (B), L.P.; MPM ASSET MANAGEMENT INVESTORS BV2018 LLC | 10% owner | Open-market sale | 26,522 | $7.54 | $200.0K | Form 4 |
| 2026-08-24 | MPM BIOVENTURES 2018, L.P.; MPM BioVentures 2018 LLC; MPM BioVentures 2018 GP LLC | 10% owner | Open-market sale | 21,623 | $7.34 | $158.7K | Form 4 |
| 2026-08-24 | MPM BioVentures 2014, L.P.; EVNIN LUKE; GADICKE ANSBERT; Foley Todd; MPM BioVentures 2014 (B), L.P.; MPM Asset Management Investors BV2014 LLC; MPM BioVentures 2014 LLC; MPM BioVentures 2014 GP LLC; MPM BIOVENTURES 2018 (B), L.P.; MPM ASSET MANAGEMENT INVESTORS BV2018 LLC | 10% owner | Open-market sale | 21,623 | $7.34 | $158.7K | Form 4 |
| 2026-08-10 | PARMAR KUSH | Director | Open-market sale | 92,444 | $7.00 | $647.1K | Form 4 |
| 2026-08-07 | 5AM Ventures V, L.P.; 5AM Partners V, LLC; 5AM Opportunities I, L.P.; 5AM Opportunities I (GP), LLC; ROCKLAGE SCOTT M; Schwab Andrew J. | 10% owner | Open-market sale | 52,317 | $6.85 | $358.4K | Form 4 |
| 2026-08-07 | PARMAR KUSH | Director | Open-market sale | 52,317 | $6.85 | $358.4K | Form 4 |
| 2026-08-06 | 5AM Ventures V, L.P.; 5AM Partners V, LLC; 5AM Opportunities I, L.P.; 5AM Opportunities I (GP), LLC; ROCKLAGE SCOTT M; Schwab Andrew J. | 10% owner | Open-market sale | 10,494 | $7.00 | $73.5K | Form 4 |
| 2026-08-06 | PARMAR KUSH | Director | Open-market sale | 10,494 | $7.00 | $73.5K | Form 4 |
| 2026-07-31 | PARMAR KUSH | Director, 10% owner | Open-market sale | 1,718 | $6.85 | $11.8K | Form 4 |
| 2026-07-31 | 5AM Ventures V, L.P.; 5AM Partners V, LLC; 5AM Opportunities I, L.P.; 5AM Opportunities I (GP), LLC; ROCKLAGE SCOTT M; Schwab Andrew J. | 10% owner | Open-market sale | 1,718 | $6.85 | $11.8K | Form 4 |
| 2026-07-30 | PARMAR KUSH | Director, 10% owner | Open-market sale | 114,756 | $6.93 | $795.3K | Form 4 |
| 2026-07-30 | 5AM Ventures V, L.P.; 5AM Partners V, LLC; 5AM Opportunities I, L.P.; 5AM Opportunities I (GP), LLC; ROCKLAGE SCOTT M; Schwab Andrew J. | 10% owner | Open-market sale | 114,756 | $6.93 | $795.3K | Form 4 |
| 2026-06-10 | Zeiher Bernhardt G | Director | Grant / award / vesting (derivative) | 19,000 | — | $0 | Form 4 |
| 2026-06-10 | Thistle Mary | Director | Grant / award / vesting (derivative) | 19,000 | — | $0 | Form 4 |
| 2026-06-10 | Radhakrishnan Maha | Director | Grant / award / vesting (derivative) | 19,000 | — | $0 | Form 4 |
| 2026-06-10 | Chapman Gina | Director | Grant / award / vesting (derivative) | 19,000 | — | $0 | Form 4 |
| 2026-06-10 | KIM PETER S | Director | Grant / award / vesting (derivative) | 19,000 | — | $0 | Form 4 |
| 2026-06-10 | PARMAR KUSH | Director, 10% owner | Grant / award / vesting (derivative) | 19,000 | — | $0 | Form 4 |
| 2026-05-20 | Zeiher Bernhardt G | Director | Open-market purchase | 5,000 | $5.86 | $29.3K | Form 4 |
| 2026-05-04 | Dowden Nathan J | Officer (President & COO) | Option exercise / conversion (derivative) | 15,000 | — | $0 | Form 4 |
| 2026-05-04 | Dowden Nathan J | Officer (President & COO) | Open-market sale | 15,000 | $15.33 | $230.0K | Form 4 |
| 2026-05-04 | Dowden Nathan J | Officer (President & COO) | Option exercise / conversion | 15,000 | $1.74 | $26.1K | Form 4 |
| 2026-05-04 | Sethuraman Natarajan | Officer (President, Research & Develop.) | Open-market sale | 25,907 | $15.39 | $398.8K | Form 4 |
| 2026-04-01 | WENTWORTH KORY JAMES | Officer (Chief Financial Officer) | Open-market sale | 2,500 | $12.95 | $32.4K | Form 4 |
| 2026-03-10 | WENTWORTH KORY JAMES | Officer (Chief Financial Officer) | Open-market sale | 11,388 | $13.02 | $148.2K | Form 4 |
| 2026-03-10 | Dowden Nathan J | Officer (President & COO) | Open-market sale | 11,894 | $13.05 | $155.2K | Form 4 |
| 2026-03-09 | WENTWORTH KORY JAMES | Officer (Chief Financial Officer) | Open-market sale | 5,089 | $13.00 | $66.2K | Form 4 |
| 2026-03-09 | Dowden Nathan J | Officer (President & COO) | Open-market sale | 3,116 | $13.02 | $40.6K | Form 4 |
Ask the chat about TRDA's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: ENTRADA THERAPEUTICS INC (TRDA).
Last updated 2026-09-09 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.